KKR-backed Biosynth, a supplier of critical raw materials to the life science industry, completed the acquisition of celares, a developer and manufacturer of conjugate vaccines and bioconjugate drugs. Financial terms were not disclosed. “celares is an established leader in bioconjugation and we are extremely excited to be acquiring such a great team of specialists. celares is a perfect complement to our wider business, enabling us to provide bioconjugation services and the production of PEGylation reagents and polymers for drug delivery. Together, we can support customers from development to commercialisation. celares is a perfect fit for Biosynth - where chemistry meets biology,” Urs Spitz, Biosynth CEO and President.